CDK4 and interstitial lung disease: In FAERS, 96% of CDK4/6 inhibitor-induced ILD cases occurred in patients aged 50 and over; the rate of ILD caused by CDK4/6 inhibitors was approximately 2.1% in those using abemaciclib and 0.3% in those using palbociclib/ribociclib, CDK4/6 inhibitor-induced deaths were reported in 18 patients using abemaciclib, 24 patients using palbociclib, and 5 patients using ribociclib [27].